In 2020, epidemiological modelling went from relative obscurity to being central in helping governments, and the public, understand COVID-19 as it spread around the world. In 2021, with the emergence of effective COVID-19 vaccines, Health Technology Assessment (HTA) will be critical to making the best possible decisions in bringing the pandemic under control, particularly in low-and middle-income countries (LMICs). In this blog we look at the potential of HTA to inform how much vaccine countries should buy, who should pay, and how vaccines can be most effectively delivered.
CGD Policy Blogs
We Can Stop Preventable COVID Deaths by Urgently Prioritising Medical Oxygen and Essential Critical Care
The COVID-19 pandemic is a critical illness crisis, with more than two million deaths worldwide and hospitals overburdened with 67 percent of COVID-19 admissions requiring oxygen. With the emergence of new variants and the rise of second or third epidemic waves, there is unprecedented demand for oxygen as a life-sustaining, first-line therapeutic and an essential resource when caring for the critically ill.
Following the UK government’s decision to cut aid from 0.7 to 0.5 percent of GNI, recent announcements have shown that bilateral aid is likely to receive the biggest hit, all while in the midst of a global pandemic.
The UK example has some key lessons for all countries (including the UK itself) who are considering how to improve their current response, and how to “build back better” and prepare for future pandemics.
We Must Stop Flying Blind: Building on Existing Systems In Low- and Middle-Income Countries To Improve the COVID-19 Response
COVID- 19 has brought a sense of urgency to decision-making that typically would have taken many months and years of deliberation. Central to this uncertainty is the glaring lack of knowledge on just how big the burden of COVID-19 truly is. The pandemic has highlighted concerning gaps in data and weaknesses in surveillance systems that have long hampered public health systems globally, especially in low- and middle- income countries (LMIC).
As the world battles COVID-19, practical investments are urgently needed to ensure that decision-makers consult the best and most relevant evidence on COVID-19 before making a decision.
The authors look at the feasibility of the drug dexamethasone in low-income countries.
Following precedents applied first in wealthy states, more than 140 countries have applied some form of lockdown restrictions to slow their COVID-19 epidemics, but can control measures be made sustainable in low-income countries?
With a focus on tests, treatments, and a vaccine, we take a look at the emerging global clinical and economic evidence-base underpinning some of these technologies, the mechanisms (mostly global) for financing these commodities, and, finally, the decision-making processes for selecting technologies. This includes identifying the right subpopulations and negotiating a cost-effective tiered price across countries and regions.
Maintaining Essential Services in the Time of COVID-19: Vaccination Delivery in Low- and Middle-Income Countries
As we observe World Immunisation Week, the implications of COVID-19’s spread for routine childhood vaccination delivery are already becoming clear.